EP2743275B1 - Pharmaceutical composition containing honeysuckle extract and antibiotics, pharmaceutical kit, and medical use of honeysuckle extract - Google Patents
Pharmaceutical composition containing honeysuckle extract and antibiotics, pharmaceutical kit, and medical use of honeysuckle extract Download PDFInfo
- Publication number
- EP2743275B1 EP2743275B1 EP11870857.7A EP11870857A EP2743275B1 EP 2743275 B1 EP2743275 B1 EP 2743275B1 EP 11870857 A EP11870857 A EP 11870857A EP 2743275 B1 EP2743275 B1 EP 2743275B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bacterium
- antibiotic
- honeysuckle
- honeysuckle extract
- extractum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims description 103
- 239000003242 anti bacterial agent Substances 0.000 title claims description 50
- 229940088710 antibiotic agent Drugs 0.000 title claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 23
- 241000205585 Aquilegia canadensis Species 0.000 title 2
- 241001570521 Lonicera periclymenum Species 0.000 claims description 120
- 241000894006 Bacteria Species 0.000 claims description 119
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 93
- 230000003115 biocidal effect Effects 0.000 claims description 68
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 40
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- LCTYGGXMQYUYHL-UHFFFAOYSA-N Secologaninsaeure Natural products OC1C(O)C(O)C(CO)OC1OC1C(C=C)C(CC(O)OC2=O)C2=CO1 LCTYGGXMQYUYHL-UHFFFAOYSA-N 0.000 claims description 36
- PUEUIRDVQIKCCG-UHFFFAOYSA-N secologanic acid Natural products OC1C(O)C(O)C(CO)OC1OC1C(C=C)C(CC=O)C(C(O)=O)=CO1 PUEUIRDVQIKCCG-UHFFFAOYSA-N 0.000 claims description 36
- 239000007864 aqueous solution Substances 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 229960000723 ampicillin Drugs 0.000 claims description 29
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 29
- 241000196324 Embryophyta Species 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 229960003405 ciprofloxacin Drugs 0.000 claims description 20
- 229960003276 erythromycin Drugs 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 18
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 17
- 229930182566 Gentamicin Natural products 0.000 claims description 17
- 229960004821 amikacin Drugs 0.000 claims description 17
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 17
- 229960002518 gentamicin Drugs 0.000 claims description 17
- 241000191967 Staphylococcus aureus Species 0.000 claims description 16
- 229960000484 ceftazidime Drugs 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 15
- -1 penam sulfone Chemical class 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 15
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims description 14
- 239000004098 Tetracycline Substances 0.000 claims description 14
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 14
- 229960002100 cefepime Drugs 0.000 claims description 14
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims description 14
- 229960004261 cefotaxime Drugs 0.000 claims description 14
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims description 14
- 229960002682 cefoxitin Drugs 0.000 claims description 14
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 claims description 14
- 229960004755 ceftriaxone Drugs 0.000 claims description 14
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 14
- 229940047766 co-trimoxazole Drugs 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 229960002182 imipenem Drugs 0.000 claims description 14
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 14
- 229960000564 nitrofurantoin Drugs 0.000 claims description 14
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 14
- 229960002292 piperacillin Drugs 0.000 claims description 14
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims description 14
- 229960002180 tetracycline Drugs 0.000 claims description 14
- 229930101283 tetracycline Natural products 0.000 claims description 14
- 235000019364 tetracycline Nutrition 0.000 claims description 14
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 13
- 229960001668 cefuroxime Drugs 0.000 claims description 13
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 13
- 239000011347 resin Substances 0.000 claims description 13
- 229920005989 resin Polymers 0.000 claims description 13
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 12
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 12
- 238000004587 chromatography analysis Methods 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 235000008216 herbs Nutrition 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 229960004023 minocycline Drugs 0.000 claims description 12
- 244000167230 Lonicera japonica Species 0.000 claims description 11
- 235000017617 Lonicera japonica Nutrition 0.000 claims description 11
- 229930182555 Penicillin Natural products 0.000 claims description 11
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 11
- 229960001139 cefazolin Drugs 0.000 claims description 11
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 11
- 229960005091 chloramphenicol Drugs 0.000 claims description 11
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 229940049954 penicillin Drugs 0.000 claims description 11
- 238000001179 sorption measurement Methods 0.000 claims description 11
- WIKQLQXZUYAZQC-WYWOCYEQSA-N (2s,5r)-3,3-dimethyl-4,4,7-trioxo-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(6r,7r)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[ Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21.O=C1C(=O)N(CC)CCN1C(=O)NC(C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 WIKQLQXZUYAZQC-WYWOCYEQSA-N 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims description 10
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 10
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 10
- 206010035664 Pneumonia Diseases 0.000 claims description 10
- 108010059993 Vancomycin Proteins 0.000 claims description 10
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 10
- 229960003644 aztreonam Drugs 0.000 claims description 10
- 229960003324 clavulanic acid Drugs 0.000 claims description 10
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 10
- 229960002227 clindamycin Drugs 0.000 claims description 10
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 10
- 229960003376 levofloxacin Drugs 0.000 claims description 10
- 235000014666 liquid concentrate Nutrition 0.000 claims description 10
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 10
- 229960001180 norfloxacin Drugs 0.000 claims description 10
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 10
- 229960001019 oxacillin Drugs 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 10
- 229960001225 rifampicin Drugs 0.000 claims description 10
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 10
- 238000010898 silica gel chromatography Methods 0.000 claims description 10
- 229960000707 tobramycin Drugs 0.000 claims description 10
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 10
- 229960003165 vancomycin Drugs 0.000 claims description 10
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 10
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 10
- 241000589516 Pseudomonas Species 0.000 claims description 9
- 229960002260 meropenem Drugs 0.000 claims description 9
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 9
- 150000003522 tetracyclines Chemical class 0.000 claims description 9
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 229960003022 amoxicillin Drugs 0.000 claims description 8
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 8
- 229960000534 cefuroxime sodium Drugs 0.000 claims description 8
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 8
- 210000002345 respiratory system Anatomy 0.000 claims description 8
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims description 8
- 229960004659 ticarcillin Drugs 0.000 claims description 8
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 229960003085 meticillin Drugs 0.000 claims description 7
- 229960005256 sulbactam Drugs 0.000 claims description 7
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims description 7
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims description 7
- 229960003865 tazobactam Drugs 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 238000005227 gel permeation chromatography Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 244000063299 Bacillus subtilis Species 0.000 claims description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 2
- 206010005940 Bone and joint infections Diseases 0.000 claims description 2
- 208000014912 Central Nervous System Infections Diseases 0.000 claims description 2
- 241000588921 Enterobacteriaceae Species 0.000 claims description 2
- 241000192125 Firmicutes Species 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 208000010315 Mastoiditis Diseases 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 2
- 206010062255 Soft tissue infection Diseases 0.000 claims description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 2
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 2
- 208000019836 digestive system infectious disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000019258 ear infection Diseases 0.000 claims description 2
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 2
- 210000001595 mastoid Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 206010040872 skin infection Diseases 0.000 claims description 2
- 208000019206 urinary tract infection Diseases 0.000 claims description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims 4
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 13
- 230000035945 sensitivity Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 229940104641 piperacillin / tazobactam Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 229940043312 ampicillin / sulbactam Drugs 0.000 description 5
- NWOYIVRVSJDTLK-YSDBFZIDSA-L disodium;(2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylate Chemical compound [Na+].[Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 NWOYIVRVSJDTLK-YSDBFZIDSA-L 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- DWHGNUUWCJZQHO-ZVDZYBSKSA-M potassium;(2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 DWHGNUUWCJZQHO-ZVDZYBSKSA-M 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000208828 Caprifoliaceae Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 3
- 229960004682 cefoperazone Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229940046284 zinacef Drugs 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000245240 Lonicera Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002322 anti-exudative effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229930185107 quinolinone Natural products 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention belongs to the technical field of pharmaceutics. Specifically, the present invention relates to a pharmaceutical composition containing an antibiotic and a honeysuckle extract which is prepared by extracting from traditional Chinese medicine of honeysuckle, its original plant of lonicera japonica or congeneric plants and purifying, and the pharmaceutical composition for use in preventing and/or treating diseases caused by bacteria. In addition, the present invention also relates to a use of the honeysuckle extract for preparation of drugs.
- the name of Chinese traditional herb “Honeysuckle” originates from “Compendium of Materia Medica”, and is the general designation of Chinese herbs and plants.
- the honeysuckle of plants is also known as lonicera japonica, which is a perennial semi-evergreen twining woody liana of caprifoliaceae.
- Lonicera japonica is named as honeysuckle owing to blooming initially white flower, and then changing into yellow flower.
- Honeysuckle of herbs is the plant of lonicera japonica of lonicera linn in caprifoliaceae and dried buds or primal flowers of congeneric plants.
- Honeysuckle has been praised as excellent medicine with heat-clearing and detoxifying effect since ancient times, which is one of medicines commonly used for heat-clearing and detoxifying in traditional Chinese medicine. Since thousands of years, honeysuckle has been playing a prominent effect in clinic, and well-loved in the doctor and patient populations. Honeysuckle, sweet in taste, cold in nature and having aromatic scent, can clear heat without hurting stomach, and not only has aromatic scent but also can eliminate pathogenic factors. Honeysuckle not only can dissipate wind-heat, but also is good at detoxification of blood, and is therefore used for treating various febrile diseases such as fever, eruption, skin patch, heat toxic swelling sore, and sore throat and the treatment effect is significant.
- honeysuckle has significant antipyretic and anti-inflammatory effects
- intraperitoneal injection of 0.25g/kg honeysuckle extract can inhibit rat swollen feet caused by carrageenan
- injection of 30-40g/kg honeysuckle extract can alleviate degree of egg white foot swelling
- injection of 8g/kg honeysuckle extract twice a day also has significant anti-exudative and anti-proliferative effects on rat croton oil granuloma pouch.
- honeysuckle has important regulatory effect on body immune system, and honeysuckle decoction promotes the phagocytosis of white blood cells; intraperitoneal injection of honeysuckle also has significant effect on promoting phagocytosis of inflammatory cells.
- honeysuckle contains organic acids, triterpenoid saponins, flavonoids and glycosides thereof, iridoid glycosides, volatile oils and so on.
- Research has been carried out currently to extract the active ingredients of honeysuckle and prove their efficacy, but so far, there has been no report of enhancing the sensitivity of bacteria to antibiotics by using honeysuckle extract in combination with antibiotics.
- honeysuckle extract is prepared by extracting from honeysuckle, its original plants of lonicera japonica or other congeneric plants, with NYCoganic acid as its active ingredient.
- It is still yet another object of the present invention is to provide a use of a honeysuckle extract containing iridoid compounds in the preparation of drugs for reversing resistance of bacteria.
- the present invention provides a pharmaceutical composition for preventing and/or treating a disease caused by a bacterium
- the pharmaceutical composition comprises a honeysuckle extract containing iridoid compounds and an antibiotic; wherein the honeysuckle extract containsrectoganic acid represented by the following structural formula (1): wherein in formula (1), X 1 and X 2 each independently represent O, and R represents H and wherein the honeysuckle extract contains 50 wt% or more of horrnic acid represented by formula (1).
- the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and/or excipient.
- preventing and/or treating a disease caused by a bacterium is achieved by reversing resistance of bacteria. Therefore, when bacteria develop resistance to antibiotics, the pharmaceutical composition can reverse or confront the drug resistance of bacteria.
- the present invention provides a pharmaceutical kit for preventing and/or treating a disease caused by a bacterium
- the pharmaceutical kit comprises a honeysuckle extract containing iridoid compounds and an antibiotic which are placed separately; wherein the honeysuckle extract contains townoganic acid represented by the following structural formula (1): wherein in formula (1), X 1 and X 2 each independently represent O, and R represents H and wherein the honeysuckle extract contains 50 wt% or more of horrnic acid represented by formula (1).
- the kit can be used for preventing and/or treating a disease caused by a bacterium in a patient in need thereof, wherein the honeysuckle extract and antibiotic may be administered to a patient simultaneously, continuously or sequentially at a time interval.
- the honeysuckle extract can enhance, restore and/or improve the sensitivity of bacteria to antibiotics, and reverse and confront resistance of bacteria to antibiotics, thereby enhancing effects of antibiotics on killing or inhibiting bacteria.
- the main active ingredient of the honeysuckle extract is perennialoganic acid.
- the honeysuckle extract contains 50 wt% or more oflloganic acid; preferably, the honeysuckle extract contains 70 wt% or more ofILLoganic acid; more preferably, the honeysuckle extract contains 80 wt% or more of NYCoganic acid; and most preferably, the honeysuckle extract contains 90 wt% or more of NYCoganic acid.
- honeysuckle extract of the present invention can be prepared according to the method disclosed in the patent ZL200610083556.7. According to embodiments of the present invention, the honeysuckle extract is prepared by a method comprising the following steps:
- the antibiotic of the present invention is selected from one or more of the group consisting of ampicillin, penam sulfone, piperacillin, tazobactam, amoxicillin, clavulanic acid, cefazolin, cefuroxime, ceftriaxone, cefuroxime sodium, sulperazon, levofloxacin, cefotaxime, ceftazidime, imipenem, cefepime, cefoxitin, gentamicin, amikacin, ciprofloxacin, chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, nitrofurantoin, aztreonam, ciprofloxacin, norfloxacin, sulbactam, ticarcillin, clavulanic acid, tobramycin, tazocin, minocycline, meropenem, penicillin, oxacillin, erythromycin, van
- the antibiotic is ampicillin and/or erythromycin.
- the present invention provides a pharmaceutical composition and pharmaceutical kit for use in preventing and/or treating a disease caused by a bacterium.
- the bacterium may be an antibiotic-resistant bacterium, preferably multiple antibiotic-resistant bacterium; more preferably, the bacterium may be a multiple antibiotic-resistant gram-negative bacterium; further preferably, the multiple antibiotic-resistant gram-negative bacterium is selected from one or more of the group consisting of Escherichia coli, Pseudomona aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Proteus bacillus, enterobacteriaceae, Haemophilus influenzae, pneumobacillus and catarrhalis ; more preferably, the multiple antibiotic-resistant gram-negative bacterium is Escherichia coli, Pseudomona aeruginosa and/or Klebsiella pneumoniae.
- the bacterium is a multiple antibiotic-resistant gram-positive bacterium; preferably, the multiple antibiotic-resistant gram-positive bacterium may be selected from one or more of the group consisting of Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Group A Streptococcus pyogenes, Streptococcus pneumoniae, Bacillus subtilis and Staphylococcus epidermidis ; further preferably, the multiple antibiotic-resistant gram-positive bacterium is methicillin-resistant Staphylococcus aureus and/or Staphylococcus aureus.
- the disease caused by a bacterium is an infectious disease caused by a bacterium, especially the infectious diseases caused by antibiotic-resistant bacteria, such as digestive system infection; blood system infection; respiratory system infection; urinary tract infection; central nervous system infection; bone and joint infection; ear, mastoid and sinus infection; and skin and soft tissue infection; preferably, the disease caused by a bacterium is respiratory system infection caused by the antibiotic-resistant bacterium.
- the disease caused by a bacterium may be respiratory system infection caused by a multiple antibiotic-resistant gram-negative bacterium; preferably, the disease caused by a bacterium is infectious pneumonia caused by a multiple antibiotic-resistant gram-negative bacterium; further preferably, the disease caused by a bacterium is nosocomial infectious pneumonia caused by a multiple antibiotic-resistant gram-negative bacterium; more preferably, the disease caused by a bacterium is nosocomial infectious pneumonia caused by a multiple antibiotic-resistant Klebsiella pneumoniae.
- the disease caused by a bacterium may be respiratory system infection caused by a multiple antibiotic-resistant gram-positive bacterium; preferably, the disease caused by a bacterium is pneumonia caused by a multiple antibiotic-resistant gram-positive bacteria; further preferably, the disease caused by a bacterium is pneumonia caused by methicillin-resistant Staphylococcus aureus.
- the present invention also provides a use of a honeysuckle extract containing iridoid compounds in the preparation of drugs for reverting resistance of bacteria.
- the honeysuckle extract can enhance, restore and/or improve the sensitivity of bacteria to antibiotics, and thereby can be used in the preparation of drugs for reverting and confronting resistance of bacteria.
- the drug when administered to the patient, can revert or confront resistance of resistant bacteria (even multiple antibiotic-resistant bacteria) in the body of a patient to antibiotics, and can also prevent bacteria in the body of a patient from developing resistance to antibiotics.
- honeysuckle extract contains iridoid compounds represented by the following structural formula (1):
- X 1 and X 2 each independently represent O, and R represents H; and wherein the honeysuckle extract contains 50 wt% or more of horroganic acid represented by formula (1); further preferably, the honeysuckle extract contains 70wt% or more of horroganic acid; more preferably, the honeysuckle extract contains 80 wt% or more of horroganic acid; and most preferably, the honeysuckle extract contains 90 wt% or more of horrnic acid.
- honeysuckle extract of the present invention can be prepared according to the method disclosed in the patent ZL200610083556.7, which is incorporated herein by reference in its entirety. According to embodiments of the present invention, the honeysuckle extract is prepared by a method comprising the following steps:
- the resistance of bacteria is resistance of bacteria to antibiotics; preferably, the resistance of bacteria is resistance of bacteria to multiple antibiotics; further preferably, the antibiotic of the present invention is selected from one or more of the group consisting of ampicillin, penam sulfone, piperacillin, tazobactam, amoxicillin, clavulanic acid, cefazolin, cefuroxime, ceftriaxone, cefuroxime sodium, sulperazon, levofloxacin, cefotaxime, ceftazidime, imipenem, cefepime, cefoxitin, gentamicin, amikacin, ciprofloxacin, chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, nitrofurantoin, aztreonam, ciprofloxacin, norfloxacin, sulbactam, ticarcillin, clavula
- the antibiotic is ampicillin and/or erythromycin.
- the drug may further contain an antibiotic; preferably, the antibiotic is selected from one or more of the group consisting of ampicillin, penam sulfone, piperacillin, tazobactam, amoxicillin, clavulanic acid, cefazolin, cefuroxime, ceftriaxone, cefuroxime sodium, sulperazon, levofloxacin, cefotaxime, ceftazidime, imipenem, cefepime, cefoxitin, gentamicin, amikacin, ciprofloxacin, chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, nitrofurantoin, aztreonam, ciprofloxacin, norfloxacin, sulbactam, ticarcillin, tobramycin, tazocin, minocycline, meropenem, penicillin, oxacillin, erythromycin
- the present inventors extracted a honeysuckle extract mainly containing horrinous bacteria from honeysuckle herbs and purified the extract, and found in the effect experiments combining antibiotics that, the honeysuckle extract could significantly enhance, restore and/or improve sensitivity of multiple resistant bacteria to antibiotics, and reverse or confront resistance of multiple resistant bacteria to antibiotics, which is embodied in that, the antibiotic which loses its original antibacterial efficacy due to resistance of bacteria restores its effect of inhibiting bacteria by adding the honeysuckle extract under the same level of antibiotics, thus proving that the honeysuckle extract can restore or improve sensitivity of resistant bacteria to antibiotics, and therefore can be used for adjuvant therapy of infectious diseases caused by resistant bacteria.
- the experimental methods in the following examples are all conventional methods unless expressly stated.
- the experimental materials such as medicinal materials and reagent materials used in the following examples can be purchased from conventional biochemical reagent stores or pharmaceutical trading enterprises unless expressly stated.
- Honeysuckle herbs employed in the examples were purchased from Beijing Tongrentang chain drug stores, produced in the province of Henan, and processed by Bozhou City Beijing Anhui Chinese Medicine Yinpian Factory, with lot number of 200502014.
- the honeysuckle herbs were identified as dried buds of Lonicera japonica Thunb. of caprifoliaceae by Institute of Materia Medica, Chinese Academy of Medical Sciences.
- the horridoganic acid used in the examples is prepared according to the method disclosed in the patent ZL200610083556.7 by Research Department of Natural Medicinal Chemistry of Institute of Materia Medica, Chinese Academy of Medical Sciences. Though measurement, the content is determined to be 98.03% (the chromatogram is shown in Figure 6 ).
- the content of the horrin in the honeysuckle extract is determined according to the HPLC external standard method, and specifically, the following instruments and conditions are employed for measurement:
- the bacteria of Escherichia coli, Pseudomona aeruginosa, Klebsiella pneumonia and Staphylococcus aureus used in the examples are all clinical isolates (multiple resistant bacteria), which were provided by the clinical laboratory of the Fourth People's Hospital of Jinan in Shandong province, the resistances of the bacteria are shown in the tables 1, 2, 3, 4 and 5 below.
- Table 1 Background materials of Klebsiella pneumoniae Number of specimen Department Date of specimen kind of specimen AMP PIP TZP AMC CZO CXM CTX CAZ CRO IPM 31853 Internal medicine 3 2010-10-29 urine R I S S S S S S S S FEP FOX GEN AMK CIP CHL SXT TCY NIT S S S S S R I R R R Table 2: Background materials of Escherichia coli Number of specimen Department Date of specimen Kind of specimen AMP PIP TZP AMC CZO CXM CTX CAZ CRO IPM 32042 Internal medicine 6 2010-10-29 urine R R I I R R R R R R R S FEP FOX GE N AMK CIP CHL SXT TCY NIT R R R S R S R R R R R Notes of Table 1 and Table 2: R: Resistant; S: Sensitive; I: Intermediate degree (moderate resistance).
- AMP ampicillin
- PIP piperacillin
- TZP piperacillin/tazobactam
- AMC amoxicillin/clavulanic acid
- CZO cefazolin
- CXM cefuroxime
- CTX cefotaxime
- CAZ ceftazidime
- CRO ceftriaxone
- IPM imipenem
- FEP cefepime
- FOX cefoxitin
- GEN gentamicin
- AMK amikacin
- CIP ciprofloxacin
- CHL chloramphenicol
- SXT trimethoprim-sulfamethoxazole
- TCY tetracycline
- NIT nitrofurantoin.
- AK amikacin
- ATM aztreonam
- AMP ampicillin
- CRO ceftriaxone
- CLS sulperazon
- CXM cefuroxime sodium
- CAZ ceftazidime
- CTX cefotaxime
- CFP cefoperazone
- CIP ciprofloxacin
- CN gentamicin
- FEP cefepime
- LEV levofloxacin
- NOR norfloxacin
- PIP piperacillin
- SAM ampicillin/sulbactam
- TIM ticarcillin/clavulanic acid
- TOB tobramycin
- TZP tazocin
- IPM imipenem
- MH minocycline
- MEM meropenem.
- PEN penicillin
- OXA oxacillin
- SAM ampicillin/penam sulfone
- FOX cefoxitin
- GEN gentamicin
- AMK amikacin
- CIP ciprofloxacin
- ERY erythromycin
- VAN vancomycin
- RIF rifampin
- SXT trimethoprim-sulfamethoxazole
- TCY tetracycline
- CLI clindamycin
- NIT nitrofurantoin.
- Culture medium MH broth.
- Honeysuckle herbs 500g were taken, pulverized coarsely, and extracted twice with 50% (v/v) ethanol aqueous solution which is 13 times the dry weight of honeysuckle herbs, each extraction was performed for 1 hour.
- the extracts were combined, and concentrated under reduced pressure to obtain a thick extractum, then the extractum was added with 450ml distilled water and dissolved by heating, then cooled to room temperature, left to stand for 24 hours and filtered to obtain a clear solution.
- the clear solution was concentrated under reduced pressure to dryness, and added with 1600ml of 95%(v/v) ethanol aqueous solution, and stirred sufficiently to be dissolved, and also the solution was slowly added with distilled water to make it contain 75%(v/v) ethanol, then left to stand for 24 hours and filtered to collect the filtrate, then ethanol was recovered from the filtrate under reduced pressure until the fluid extractum was formed.
- the fluid extractum was added with 500ml water, dissolved and filtered, then the filtrate was passed through the pretreated SP-825 styrene macroporous adsorption resin chromatographic column, and the column was eluted sequentially with 5 times the amount of the resin column volumes of water and 6 times the amount of the resin column volumes of 20% (v/v) ethanol aqueous solution, and then ethanol was recovered from the eluate under reduced pressure, until there was no alcohol flavor, and freeze-drying was performed.
- honeysuckle extract N1 was determined to contain 90.67% continuationoganic acid according to the HPLC external standard method by using continuationoganic acid as the reference object (the chromatogram is shown in Figure 1 ).
- the activated bacterium suspension was diluted to a concentration equivalent to 0.5 McFarland turbidity standard, and diluted with the culture medium of MH broth in a proportion of 1:1000, and then added into each well in amount of 100 ⁇ L per well.
- the antibiotics resisted by the above four multiple resistant bacteria were diluted to 1:2048 (2 -11 ) from 1mg/mL (initial concentration) by 2-fold dilution, and then the original solution and different concentrations of diluted antibiotics were added respectively into the well containing the bacterium suspension, with each well added with 100 ⁇ L, and the minimum inhibitory concentration (MIC) of each antibiotic was recorded finally.
- bacterium solution control that is, bacterium solution plus an equal volume of culture medium
- a blank culture medium control was set.
- Table 5 Bacteria and antibiotics for the experiment of combined effects Bacteria Antibiotics Klebsiella pneumoniae ampicillin Staphylococcus aureus erythromycin Escherichia coli ampicillin Pseudomona aeruginosa ampicillin
- the antibiotics in Table 5 were diluted to 2 -5 from 1mg/mL (initial concentration) by 2-fold dilution, and then added into the 96-well plate successively in transverse direction in amount of 100 ⁇ l per well.
- the antibiotic of each dilution was added into three wells.
- the test sample of honeysuckle extract N1 prepared in Example 1 was diluted with PBS to a concentration of 40mg/ml, and then diluted by 2-fold serial dilution (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128), followed by added into each well in amount of 100 ⁇ l per well.
- Cultivation was performed at 37 °C for 20h, and the absorbance was detected at 600nm by a spectrophotometer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Description
- The present invention belongs to the technical field of pharmaceutics. Specifically, the present invention relates to a pharmaceutical composition containing an antibiotic and a honeysuckle extract which is prepared by extracting from traditional Chinese medicine of honeysuckle, its original plant of lonicera japonica or congeneric plants and purifying, and the pharmaceutical composition for use in preventing and/or treating diseases caused by bacteria. In addition, the present invention also relates to a use of the honeysuckle extract for preparation of drugs.
- In recent years, the problem of intensive use of a large number of antibiotics in medical practice has become increasingly serious. Improper use of antibiotics exerts a selective evolutionary pressure on microorganisms, especially bacteria, resulting in a sharp increase in the number and species of resistant bacteria, even causing a "superbug" which can resist a variety of antibiotics. In general, most new antibiotics will lose their original efficacy within a number of years due to appearance of drug resistance of pathogens. For example, penicillin-resistant Streptococcus pneumoniae is very sensitive to drugs such as penicillin, erythromycin and sulfanilamide in the past, but is almost ineffective now. For another example, common sources of infection such as Staphylococcus aureus, Streptococcus pneumoniae, Genus Enterococcus and Pseudomona aeruginosa gradually become multi-resistant, and have resistances to the commonly used β-lactams, quinolinone, novel macrolides and cephalosporins, even vancomycin. For yet another example, data indicate that resistances of Pseudomonas aeruginosa to eight antibiotics such as amoxicillin and zinacef reach 100%, and resistances of Klebsiella pneumoniae to 16 high-grade antibiotics such as zinacef and fortum reach up to 51.85-100%. While methicillin-resistant Staphylococcus aureus can only be cured by vancomycin.
- Generation of a large number of resistant bacteria brings about more and more intractable infections, resulting in increasingly more risks of bacterial infection and increasingly more costs on treatment of infectious diseases. How to reduce resistance of bacteria to antibiotics and increase sensitivity of bacteria to antibiotics has become a problem of great concern in the medical field.
- The name of Chinese traditional herb "Honeysuckle" originates from "Compendium of Materia Medica", and is the general designation of Chinese herbs and plants. The honeysuckle of plants is also known as lonicera japonica, which is a perennial semi-evergreen twining woody liana of caprifoliaceae. Lonicera japonica is named as honeysuckle owing to blooming initially white flower, and then changing into yellow flower. Honeysuckle of herbs is the plant of lonicera japonica of lonicera linn in caprifoliaceae and dried buds or primal flowers of congeneric plants.
- Honeysuckle has been praised as excellent medicine with heat-clearing and detoxifying effect since ancient times, which is one of medicines commonly used for heat-clearing and detoxifying in traditional Chinese medicine. Since thousands of years, honeysuckle has been playing a prominent effect in clinic, and well-loved in the doctor and patient populations. Honeysuckle, sweet in taste, cold in nature and having aromatic scent, can clear heat without hurting stomach, and not only has aromatic scent but also can eliminate pathogenic factors. Honeysuckle not only can dissipate wind-heat, but also is good at detoxification of blood, and is therefore used for treating various febrile diseases such as fever, eruption, skin patch, heat toxic swelling sore, and sore throat and the treatment effect is significant. Modern research preliminarily discusses the heat-clearing and detoxifying mechanisms of honeysuckle. For example, honeysuckle has significant antipyretic and anti-inflammatory effects, intraperitoneal injection of 0.25g/kg honeysuckle extract can inhibit rat swollen feet caused by carrageenan; injection of 30-40g/kg honeysuckle extract can alleviate degree of egg white foot swelling; and injection of 8g/kg honeysuckle extract twice a day also has significant anti-exudative and anti-proliferative effects on rat croton oil granuloma pouch. It is also considered that honeysuckle has important regulatory effect on body immune system, and honeysuckle decoction promotes the phagocytosis of white blood cells; intraperitoneal injection of honeysuckle also has significant effect on promoting phagocytosis of inflammatory cells.
- Studies on the chemical compositions of honeysuckle show that, honeysuckle contains organic acids, triterpenoid saponins, flavonoids and glycosides thereof, iridoid glycosides, volatile oils and so on. Research has been carried out currently to extract the active ingredients of honeysuckle and prove their efficacy, but so far, there has been no report of enhancing the sensitivity of bacteria to antibiotics by using honeysuckle extract in combination with antibiotics. However, Chen Yiqiang et al (2004): "In vitro effects of honeysuckle aqueous-extracts alone and in combination with ceftazidime on Pseudomonas aeruginosa biofilm", Chinese Journal of Microbiology and Immunology, Vol. 24, pp. 738-742 and Qin et al. (2003): "Inhibitory and Destructive Effect of Honeysuckle Aqueous Extracts on Biofilm Formation by Pseudomonas Aeruginosa in Vitro", Master Thesis, CN disclose the effects of honeysuckle extracts on biofilm caused by Pseudomonas aeruginosa, a gram-negative bacterium, alone and in combination with ceftazidime.
- It is an object of the present invention to provide a pharmaceutical composition containing a honeysuckle extract and an antibiotic. Wherein the honeysuckle extract is prepared by extracting from honeysuckle, its original plants of lonicera japonica or other congeneric plants, with secologanic acid as its active ingredient.
- It is another object of the present invention to provide a pharmaceutical kit comprising a honeysuckle extract and an antibiotic which are separately placed.
- It is yet another object of the present invention to provide a use of the pharmaceutical composition and pharmaceutical kit in the preparation of drugs for preventing and/or treating a disease caused by a bacterium.
- It is still yet another object of the present invention is to provide a use of a honeysuckle extract containing iridoid compounds in the preparation of drugs for reversing resistance of bacteria.
- The technical solutions of the present invention are as follows:
- In one aspect, the present invention provides a pharmaceutical composition for preventing and/or treating a disease caused by a bacterium, the pharmaceutical composition comprises a honeysuckle extract containing iridoid compounds and an antibiotic; wherein the honeysuckle extract contains secologanic acid represented by the following structural formula (1):
- Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and/or excipient.
- Wherein preventing and/or treating a disease caused by a bacterium is achieved by reversing resistance of bacteria. Therefore, when bacteria develop resistance to antibiotics, the pharmaceutical composition can reverse or confront the drug resistance of bacteria.
- In another aspect, the present invention provides a pharmaceutical kit for preventing and/or treating a disease caused by a bacterium, the pharmaceutical kit comprises a honeysuckle extract containing iridoid compounds and an antibiotic which are placed separately; wherein the honeysuckle extract contains secologanic acid represented by the following structural formula (1):
- The main active ingredient of the honeysuckle extract is secologanic acid.
- The honeysuckle extract contains 50 wt% or more of secologanic acid; preferably, the honeysuckle extract contains 70 wt% or more of secologanic acid; more preferably, the honeysuckle extract contains 80 wt% or more of secologanic acid; and most preferably, the honeysuckle extract contains 90 wt% or more of secologanic acid.
- The honeysuckle extract of the present invention can be prepared according to the method disclosed in the patent ZL200610083556.7. According to embodiments of the present invention, the honeysuckle extract is prepared by a method comprising the following steps:
- (1) pulverizing honeysuckle of plants, its original plant of lonicera japonica or other congeneric plants, and then performing extraction with water and/or C1-C6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain an extract;
- (2) concentrating and drying the extract obtained in step (1) under normal or reduced pressure to obtain an extractum, or performing spray-drying on the extract obtained in step (1) to obtain powder, and dissolving the extractum or powder with water, then carrying out precipitation or settlement with C1-C6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain a precipitate or a dissolving liquid concentrate;
- (3) isolating and purifying the precipitate or dissolving liquid concentrate obtained in step (2) by chromatography, and collecting eluate containing iridoid compounds, wherein the chromatography is selected from one or more of macroporous adsorption resin column chromatography, normal phase silica gel chromatography and reversed phase silica gel chromatography;
- (1) pulverizing honeysuckle herbs and then performing extraction with 50% (v/v) ethanol aqueous solution to obtain an extracted liquid;
- (2) concentrating the extracted liquid obtained in step (1) under reduced pressure to obtain an extractum, dissolving the extractum with water, filtering, and concentrating the solution to dryness, and performing dissolution by adding 95% (v/v) ethanol aqueous solution, and adding distilled water to make the solution contain 75% (v/v) ethanol, filtering after standing, and recovering ethanol from the filtrate to obtain a fluid extractum;
- (3) dissolving the fluid extractum obtained in step (2) by adding water and filtering to obtain a filtrate, and making the filtrate pass through a styrene macroporous adsorption resin chromatographic column, and then eluting the column sequentially with water and 20% (v/v) ethanol aqueous solution, and recovering ethanol in the eluate of 20% (v/v) ethanol aqueous solution;
- The antibiotic of the present invention is selected from one or more of the group consisting of ampicillin, penam sulfone, piperacillin, tazobactam, amoxicillin, clavulanic acid, cefazolin, cefuroxime, ceftriaxone, cefuroxime sodium, sulperazon, levofloxacin, cefotaxime, ceftazidime, imipenem, cefepime, cefoxitin, gentamicin, amikacin, ciprofloxacin, chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, nitrofurantoin, aztreonam, ciprofloxacin, norfloxacin, sulbactam, ticarcillin, clavulanic acid, tobramycin, tazocin, minocycline, meropenem, penicillin, oxacillin, erythromycin, vancomycin, rifampin and clindamycin.
- Preferably, the antibiotic is ampicillin and/or erythromycin.
- In another aspect, the present invention provides a pharmaceutical composition and pharmaceutical kit for use in preventing and/or treating a disease caused by a bacterium.
- Preferably, the bacterium may be an antibiotic-resistant bacterium, preferably multiple antibiotic-resistant bacterium; more preferably, the bacterium may be a multiple antibiotic-resistant gram-negative bacterium; further preferably, the multiple antibiotic-resistant gram-negative bacterium is selected from one or more of the group consisting of Escherichia coli, Pseudomona aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Proteus bacillus, enterobacteriaceae, Haemophilus influenzae, pneumobacillus and catarrhalis; more preferably, the multiple antibiotic-resistant gram-negative bacterium is Escherichia coli, Pseudomona aeruginosa and/or Klebsiella pneumoniae.
- Alternatively, the bacterium is a multiple antibiotic-resistant gram-positive bacterium; preferably, the multiple antibiotic-resistant gram-positive bacterium may be selected from one or more of the group consisting of Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Group A Streptococcus pyogenes, Streptococcus pneumoniae, Bacillus subtilis and Staphylococcus epidermidis; further preferably, the multiple antibiotic-resistant gram-positive bacterium is methicillin-resistant Staphylococcus aureus and/or Staphylococcus aureus.
- In addition, in the use according to the present invention, the disease caused by a bacterium is an infectious disease caused by a bacterium, especially the infectious diseases caused by antibiotic-resistant bacteria, such as digestive system infection; blood system infection; respiratory system infection; urinary tract infection; central nervous system infection; bone and joint infection; ear, mastoid and sinus infection; and skin and soft tissue infection; preferably, the disease caused by a bacterium is respiratory system infection caused by the antibiotic-resistant bacterium.
- Wherein the disease caused by a bacterium may be respiratory system infection caused by a multiple antibiotic-resistant gram-negative bacterium; preferably, the disease caused by a bacterium is infectious pneumonia caused by a multiple antibiotic-resistant gram-negative bacterium; further preferably, the disease caused by a bacterium is nosocomial infectious pneumonia caused by a multiple antibiotic-resistant gram-negative bacterium; more preferably, the disease caused by a bacterium is nosocomial infectious pneumonia caused by a multiple antibiotic-resistant Klebsiella pneumoniae.
- Alternatively, the disease caused by a bacterium may be respiratory system infection caused by a multiple antibiotic-resistant gram-positive bacterium; preferably, the disease caused by a bacterium is pneumonia caused by a multiple antibiotic-resistant gram-positive bacteria; further preferably, the disease caused by a bacterium is pneumonia caused by methicillin-resistant Staphylococcus aureus.
- In yet another aspect, the present invention also provides a use of a honeysuckle extract containing iridoid compounds in the preparation of drugs for reverting resistance of bacteria. Experiments show the honeysuckle extract can enhance, restore and/or improve the sensitivity of bacteria to antibiotics, and thereby can be used in the preparation of drugs for reverting and confronting resistance of bacteria. The drug, when administered to the patient, can revert or confront resistance of resistant bacteria (even multiple antibiotic-resistant bacteria) in the body of a patient to antibiotics, and can also prevent bacteria in the body of a patient from developing resistance to antibiotics.
-
- Wherein in formula (1), X1 and X2 each independently represent O, and R represents H;
and wherein the honeysuckle extract contains 50 wt% or more of secologanic acid represented by formula (1); further preferably, the honeysuckle extract contains 70wt% or more of secologanic acid; more preferably, the honeysuckle extract contains 80 wt% or more of secologanic acid; and most preferably, the honeysuckle extract contains 90 wt% or more of secologanic acid. - The honeysuckle extract of the present invention can be prepared according to the method disclosed in the patent ZL200610083556.7, which is incorporated herein by reference in its entirety. According to embodiments of the present invention, the honeysuckle extract is prepared by a method comprising the following steps:
- (1) pulverizing honeysuckle of plants, its original plant of lonicera japonica or other congeneric plants, and then performing extraction with water and/or C1-C6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain an extract;
- (2) concentrating the extract obtained in step (1) under normal or reduced pressure to obtain an extractum, or performing spray-drying on the extract obtained in step (1) to obtain powder, and dissolving the extractum or powder with water, then carrying out precipitation or settlement with C1-C6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain a precipitate or a dissolving liquid concentrate;
- (3) isolating and purifying the precipitate or dissolving liquid concentrate obtained in step (2) by chromatography, and collecting eluate containing iridoid compounds, wherein the chromatography is selected from one or more of macroporous adsorption resin column chromatography, normal phase silica gel chromatography and reversed phase silica gel chromatography;
- (1) pulverizing honeysuckle herbs with 50% (v/v) ethanol aqueous solution to obtain an extracted liquid;
- (2) concentrating the extracted liquid obtained in step (1) under reduced pressure to obtain an extractum, dissolving the extractum with water, filtering, and concentrating the solution to dryness, and performing dissolution by adding 95% (v/v) ethanol aqueous solution, and adding distilled water to make the solution contain 75% (v/v) ethanol, filtering after standing, and recovering ethanol from the filtrate to obtain a fluid extractum;
- (3) dissolving the fluid extractum obtained in step (2) by adding water and filtering to obtain a filtrate, and making the filtrate pass through a styrene macroporous adsorption resin chromatographic column, and then eluting the column sequentially with water and 20% (v/v) ethanol aqueous solution, and recovering ethanol in the eluate of 20% (v/v) ethanol aqueous solution;
- In the use according to the present invention, the resistance of bacteria is resistance of bacteria to antibiotics;
preferably, the resistance of bacteria is resistance of bacteria to multiple antibiotics;
further preferably, the antibiotic of the present invention is selected from one or more of the group consisting of ampicillin, penam sulfone, piperacillin, tazobactam, amoxicillin, clavulanic acid, cefazolin, cefuroxime, ceftriaxone, cefuroxime sodium, sulperazon, levofloxacin, cefotaxime, ceftazidime, imipenem, cefepime, cefoxitin, gentamicin, amikacin, ciprofloxacin, chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, nitrofurantoin, aztreonam, ciprofloxacin, norfloxacin, sulbactam, ticarcillin, clavulanic acid, tobramycin, tazocin, minocycline, meropenem, penicillin, oxacillin, erythromycin, vancomycin, rifampin and clindamycin. - Preferably, the antibiotic is ampicillin and/or erythromycin.
- In addition, the drug may further contain an antibiotic; preferably, the antibiotic is selected from one or more of the group consisting of ampicillin, penam sulfone, piperacillin, tazobactam, amoxicillin, clavulanic acid, cefazolin, cefuroxime, ceftriaxone, cefuroxime sodium, sulperazon, levofloxacin, cefotaxime, ceftazidime, imipenem, cefepime, cefoxitin, gentamicin, amikacin, ciprofloxacin, chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, nitrofurantoin, aztreonam, ciprofloxacin, norfloxacin, sulbactam, ticarcillin, tobramycin, tazocin, minocycline, meropenem, penicillin, oxacillin, erythromycin, vancomycin, rifampin and clindamycin; further preferably, the antibiotic is ampicillin and/or erythromycin.
- After the chlorogenic acid and its derivatives are considered to have anti-bacterial and anti-viral activity, basic researches on substances of honeysuckle having heat-clearing and detoxifying effect set off a climax, a number of research institutes or laboratories are dedicated to the isolation and extraction of the active ingredients of honeysuckle.
- Through a large number of experiments, the present inventors extracted a honeysuckle extract mainly containing secologanic acid from honeysuckle herbs and purified the extract, and found in the effect experiments combining antibiotics that, the honeysuckle extract could significantly enhance, restore and/or improve sensitivity of multiple resistant bacteria to antibiotics, and reverse or confront resistance of multiple resistant bacteria to antibiotics, which is embodied in that, the antibiotic which loses its original antibacterial efficacy due to resistance of bacteria restores its effect of inhibiting bacteria by adding the honeysuckle extract under the same level of antibiotics, thus proving that the honeysuckle extract can restore or improve sensitivity of resistant bacteria to antibiotics, and therefore can be used for adjuvant therapy of infectious diseases caused by resistant bacteria.
- Hereinafter, the examples of the present invention will be illustrated in detail in combination with the accompanying draws:
-
Figure 1 shows an HPLC chromatogram of honeysuckle extract N1 prepared in Example 1 according to the present invention, which was determined to contain 90.67% (by weight) of secologanic acid; -
Figure 2 shows experimental results of improving sensitivity of Klebsiella pneumoniae to the antibiotic "ampicillin" by using the honeysuckle extract; -
Figure 3 shows experimental results of improving sensitivity of Staphylococcus aureus to the antibiotic "erythromycin" by using the honeysuckle extract; -
Figure 4 shows experimental results of improving sensitivity of Escherichia coli to the antibiotic "ampicillin" by using the honeysuckle extract; -
Figure 5 shows experimental results of improving sensitivity of Pseudomona aeruginosa to the antibiotic "ampicillin" by using the honeysuckle extract; -
Figure 6 shows an HPLC chromatogram of secologanic acid standard employed in the example of the present invention, with a purity of 98.03% (by weight). - The present invention will be further described in detail below in conjunction with the specific embodiments, and the examples provided are only intended to illustrate the present invention.
- The experimental methods in the following examples are all conventional methods unless expressly stated. The experimental materials such as medicinal materials and reagent materials used in the following examples can be purchased from conventional biochemical reagent stores or pharmaceutical trading enterprises unless expressly stated. Wherein:
Honeysuckle herbs employed in the examples were purchased from Beijing Tongrentang chain drug stores, produced in the province of Henan, and processed by Bozhou City Beijing Anhui Chinese Medicine Yinpian Factory, with lot number of 200502014. The honeysuckle herbs were identified as dried buds of Lonicera japonica Thunb. of caprifoliaceae by Institute of Materia Medica, Chinese Academy of Medical Sciences. - The secologanic acid used in the examples, as the standard for determining the content of the extract, is prepared according to the method disclosed in the patent
ZL200610083556.7 Figure 6 ). - In the examples, the content of the secologanic acid in the honeysuckle extract is determined according to the HPLC external standard method, and specifically, the following instruments and conditions are employed for measurement:
- (1) Instrument: Agilent 1100 liquid chromatograph including quaternary pump, autosampler, DAD detector and Chemstation chromatography workstation;
- (2) Chromatographic conditions and system suitability test: the chromatographic column is Prevail C18 5µ(250mmX4.6mm) [Alltech, USA]; acetonitrile-1% glacial acetic acid aqueous solution (13:87) is used as the mobile phase, gradient elution is employed; the flow rate is 0.9 ml/min, the stopping time is 40 minutes, the equilibrium time is 10 minutes and the detection wavelength is 242 nm. The number of theoretical plates calculated by JYH peak should be no less than 1000.
- (3) Reagents: acetonitrile gradient grade for chromatography; pure water; analytical grade acetic acid.
- The bacteria of Escherichia coli, Pseudomona aeruginosa, Klebsiella pneumonia and Staphylococcus aureus used in the examples are all clinical isolates (multiple resistant bacteria), which were provided by the clinical laboratory of the Fourth People's Hospital of Jinan in Shandong province, the resistances of the bacteria are shown in the tables 1, 2, 3, 4 and 5 below.
Table 1: Background materials of Klebsiella pneumoniae Number of specimen Department Date of specimen Kind of specimen AMP PIP TZP AMC CZO CXM CTX CAZ CRO IPM 31853 Internal medicine 32010-10-29 urine R I S S S S S S S S FEP FOX GEN AMK CIP CHL SXT TCY NIT S S S S R I R R R Table 2: Background materials of Escherichia coli Number of specimen Department Date of specimen Kind of specimen AMP PIP TZP AMC CZO CXM CTX CAZ CRO IPM 32042 Internal medicine 62010-10-29 urine R R I I R R R R R S FEP FOX GE N AMK CIP CHL SXT TCY NIT R R R S R S R R R Notes of Table 1 and Table 2:
R: Resistant; S: Sensitive; I: Intermediate degree (moderate resistance).
AMP: ampicillin; PIP: piperacillin; TZP: piperacillin/tazobactam; AMC: amoxicillin/clavulanic acid; CZO: cefazolin; CXM: cefuroxime; CTX: cefotaxime; CAZ: ceftazidime; CRO: ceftriaxone; IPM: imipenem; FEP: cefepime; FOX: cefoxitin; GEN: gentamicin; AMK: amikacin; CIP: ciprofloxacin; CHL: chloramphenicol; SXT: trimethoprim-sulfamethoxazole; TCY: tetracycline; NIT: nitrofurantoin.Table 3: Background materials of Pseudomona aeruginosa Number of specimen Date of specimen AK ATM AMP CRO CLS CXM CAZ CTX CFP CIP CN 12 2007-3 S S R R S R S S S S S FEP LEV NOR PIP SAM TIM TOB TZP IPM MH S S S S R S S S S R Notes: R: Resistant; S: Sensitive; I: Intermediate degree.
AK: amikacin; ATM: aztreonam; AMP: ampicillin; CRO: ceftriaxone; CLS: sulperazon; CXM: cefuroxime sodium; CAZ: ceftazidime; CTX: cefotaxime; CFP: cefoperazone; CIP: ciprofloxacin; CN: gentamicin; FEP: cefepime; LEV: levofloxacin; NOR: norfloxacin; PIP: piperacillin; SAM: ampicillin/sulbactam; TIM: ticarcillin/clavulanic acid; TOB: tobramycin; TZP: tazocin; IPM: imipenem; MH: minocycline; MEM: meropenem.Table 4: Background materials of Staphylococcus aureus Number of specimen Department Date of specimen Kind of specimen PNE OXA SAM FOX GEN AMK CIP 31692 Surgery 42010-10-1 secretion R S S S S S S ERY VAN RIF SXT TCY CLI NIT R S S S R R S Notes: R: Resistant; S: Sensitive; I: Intermediate degree.
PEN: penicillin; OXA: oxacillin; SAM: ampicillin/penam sulfone; FOX: cefoxitin; GEN: gentamicin; AMK: amikacin; CIP: ciprofloxacin; ERY: erythromycin; VAN: vancomycin; RIF: rifampin; SXT: trimethoprim-sulfamethoxazole; TCY: tetracycline; CLI: clindamycin; NIT: nitrofurantoin.
Culture medium: MH broth. - Equipments employed in the examples:
- Constant temperature incubator: product of Shanghai Yuejin
Medical Device Factory 1. - Clean bench: product of Jinan Longhong Corporation.
- Microplate reader: product of Finland Leibo Corporation.
- 722 spectrophotometer: product of Shanghai Precision & Scientific Instrument Co., Ltd.
- -80 °C refrigerator: product of American FOMAS Corporation.
- Honeysuckle herbs (500g) were taken, pulverized coarsely, and extracted twice with 50% (v/v) ethanol aqueous solution which is 13 times the dry weight of honeysuckle herbs, each extraction was performed for 1 hour. The extracts were combined, and concentrated under reduced pressure to obtain a thick extractum, then the extractum was added with 450ml distilled water and dissolved by heating, then cooled to room temperature, left to stand for 24 hours and filtered to obtain a clear solution.
- The clear solution was concentrated under reduced pressure to dryness, and added with 1600ml of 95%(v/v) ethanol aqueous solution, and stirred sufficiently to be dissolved, and also the solution was slowly added with distilled water to make it contain 75%(v/v) ethanol, then left to stand for 24 hours and filtered to collect the filtrate, then ethanol was recovered from the filtrate under reduced pressure until the fluid extractum was formed.
- The fluid extractum was added with 500ml water, dissolved and filtered, then the filtrate was passed through the pretreated SP-825 styrene macroporous adsorption resin chromatographic column, and the column was eluted sequentially with 5 times the amount of the resin column volumes of water and 6 times the amount of the resin column volumes of 20% (v/v) ethanol aqueous solution, and then ethanol was recovered from the eluate under reduced pressure, until there was no alcohol flavor, and freeze-drying was performed.
- Further purification was performed using Sephadex LH-20 gel chromatographic column, comprising: eluting with water, collecting the sample liquid, recovering under reduced pressure, and performing freeze-drying; and the purification was performed several times through the gel chromatographic column to obtain the honeysuckle extract N1. The honeysuckle extract N1 was determined to contain 90.67% secologanic acid according to the HPLC external standard method by using secologanic acid as the reference object (the chromatogram is shown in
Figure 1 ). - In this example, bacterial inhibition effects of antibiotics on the four multiple resistant bacteria in Tables 1-4 were measured.
- The activated bacterium suspension was diluted to a concentration equivalent to 0.5 McFarland turbidity standard, and diluted with the culture medium of MH broth in a proportion of 1:1000, and then added into each well in amount of 100µL per well.
- The antibiotics resisted by the above four multiple resistant bacteria were diluted to 1:2048 (2-11) from 1mg/mL (initial concentration) by 2-fold dilution, and then the original solution and different concentrations of diluted antibiotics were added respectively into the well containing the bacterium suspension, with each well added with 100µL, and the minimum inhibitory concentration (MIC) of each antibiotic was recorded finally.
- Meanwhile, a bacterium solution control (that is, bacterium solution plus an equal volume of culture medium) and a blank culture medium control were set.
- Cultivation was performed at 37 °C for 20h, and detection was performed at 630nm by the microplate reader, and the bacterial inhibition rate is calculated according to
formula ②, and the data obtained is put intoformula ① to calculate specific distance, and the specific distance is added to the virus dilution index with pathologic rate less than 50% to obtain half inhibitory concentration (Reed-Muench method). - The results show that, as to the antibiotics resisted by the above four bacteria, except the antibiotic of ampicillin resisted by Klebsiella pneumonia, which has inhibitory effect on Klebsiella pneumoniae in the first two dilutions (1mg/mL, 0.5mg/mL), all of antibiotics resisted by the four bacteria in each dilution are resisted by the bacteria.
- The experiment of combined effects of the following antibiotics and honeysuckle extract N1 on bacteria were carried out:
Table 5: Bacteria and antibiotics for the experiment of combined effects Bacteria Antibiotics Klebsiella pneumoniae ampicillin Staphylococcus aureus erythromycin Escherichia coli ampicillin Pseudomona aeruginosa ampicillin - The antibiotics in Table 5 were diluted to 2-5 from 1mg/mL (initial concentration) by 2-fold dilution, and then added into the 96-well plate successively in transverse direction in amount of 100µl per well. The antibiotic of each dilution was added into three wells. The test sample of honeysuckle extract N1 prepared in Example 1 was diluted with PBS to a concentration of 40mg/ml, and then diluted by 2-fold serial dilution (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128), followed by added into each well in amount of 100µl per well.
- Meanwhile, an antibiotic control (replacing honeysuckle extract N1 with blank culture medium), bacterium solution control and blank culture medium control were set.
- Cultivation was performed at 37 °C for 20h, and the absorbance was detected at 600nm by a spectrophotometer.
- The results are shown in
Figure 2 to Figure 5 , wherein the antibiotic in each figure was diluted to 2-5 from 1mg/mL (initial concentration) by 2-fold dilution, therefore the abscissas 1-6 in each figure represent the concentrations of 2-1-2-5 respectively. It can be seen from the results of the figures that, addition of the honeysuckle extract significantly enhances the sensitivity of four multiple resistant bacteria to the corresponding antibiotics, therefore the honeysuckle extract can be made into the pharmaceutical composition by mixing with the antibiotic or be administered in combination with the antibiotic, so as to be used for prevention and/or treatment of diseases caused by resistant bacteria.
most preferably, the method further comprises the step of purifying the eluate containing iridoid compounds obtained in step (3) by Sephadex LH-20 gel chromatographic column and collecting the eluate of water.
most preferably, the method further comprises the step of purifying the eluate containing iridoid compounds obtained in step (3) by Sephadex LH-20 gel chromatographic column and collecting the eluate of water.
Claims (19)
- A pharmaceutical composition for preventing and/or treating a disease caused by a bacterium, comprising a honeysuckle extract containing iridoid compounds and an antibiotic; wherein the honeysuckle extract contains secologanic acid represented by the following structural formula (1):
preferably, the pharmaceutical composition further comprising a pharmaceutically acceptable carrier and/or excipient. - The pharmaceutical composition according to claim 1, wherein preventing and/or treating a disease caused by a bacterium is achieved by reversing resistance of bacteria.
- The pharmaceutical composition according to claim 1, wherein the antibiotic is selected from one or more of the group consisting of ampicillin, penam sulfone, piperacillin, tazobactam, amoxicillin, clavulanic acid, cefazolin, cefuroxime, ceftriaxone, cefuroxime sodium, sulperazon, levofloxacin, cefotaxime, ceftazidime, imipenem, cefepime, cefoxitin, gentamicin, amikacin, ciprofloxacin, chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, nitrofurantoin, aztreonam, norfloxacin, sulbactam, ticarcillin, tobramycin, tazocin, minocycline, meropenem, penicillin, oxacillin, erythromycin, vancomycin, rifampin and clindamycin;
preferably, the antibiotic is ampicillin and/or erythromycin. - The pharmaceutical composition according to claim 1, wherein the honeysuckle extract contains 70wt% or more of secologanic acid;
preferably, the honeysuckle extract contains 80 wt% or more of secologanic acid;
more preferably, the honeysuckle extract contains 90 wt% or more of secologanic acid. - The pharmaceutical composition according to claim 1, wherein the honeysuckle extract is prepared by a method comprising the following steps:(1) pulverizing honeysuckle of plants, its original plant of lonicera japonica or other congeneric plants, and then performing extraction with C1-C6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain an extract;(2) concentrating the extract obtained in step (1) under normal or reduced pressure to obtain an extractum, or performing spray-drying on the extract obtained in step (1) to obtain powder, and dissolving the extractum or powder with water, then carrying out precipitation or settlement with C1-C6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain a precipitate or a dissolving liquid concentrate;(3) isolating and purifying the precipitate or dissolving liquid concentrate obtained in step (2) by chromatography, and collecting eluate containing iridoid compounds, wherein the chromatography is selected from one or more of macroporous adsorption resin column chromatography, normal phase silica gel chromatography and reversed phase silica gel chromatography;preferably, the honeysuckle extract is prepared by a method comprising the following steps:(1) pulverizing honeysuckle herbs and then performing extraction with 50% (v/v) ethanol aqueous solution to obtain an extracted liquid;(2) concentrating the extracted liquid obtained in step (1) under reduced pressure to obtain an extractum, dissolving the extractum with water, filtering, and concentrating the solution to dryness, and performing dissolution by adding 95% (v/v) ethanol aqueous solution, and adding distilled water to make the solution contain 75% (v/v) ethanol, filtering after standing, and recovering ethanol from the filtrate to obtain a fluid extractum;(3) dissolving the fluid extractum obtained in step (2) by adding water and filtering to obtain a filtrate, and making the filtrate pass through a styrene macroporous adsorption resin chromatographic column, and then eluting the column sequentially with water and 20% (v/v) ethanol aqueous solution, and recovering ethanol in the eluate of 20% (v/v) ethanol aqueous solution;more preferably, the method further comprises the step of purifying the eluate containing iridoid compounds obtained in step (3) by gel chromatography;
most preferably, the method further comprises the step of purifying the eluate containing iridoid compounds obtained in step (3) by Sephadex LH-20 gel chromatographic column and collecting the eluate of water. - A pharmaceutical kit for preventing and/or treating a disease caused by a bacterium, comprising a honeysuckle extract containing iridoid compounds and an antibiotic which are placed separately;
wherein the honeysuckle extract contains secologanic acid represented by the following structural formula (1): - The pharmaceutical kit according to claim 6, wherein the antibiotic is selected from one or more of the group consisting of ampicillin, penam sulfone, piperacillin, tazobactam, amoxicillin, clavulanic acid, cefazolin, cefuroxime, ceftriaxone, cefuroxime sodium, sulperazon, levofloxacin, cefotaxime, ceftazidime, imipenem, cefepime, cefoxitin, gentamicin, amikacin, ciprofloxacin, chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, nitrofurantoin, aztreonam, norfloxacin, sulbactam, ticarcillin, tobramycin, tazocin, minocycline, meropenem, penicillin, oxacillin, erythromycin, vancomycin, rifampin and clindamycin;
preferably, the antibiotic is ampicillin and/or erythromycin. - The pharmaceutical kit according to claim 6, wherein the honeysuckle extract contains 70 wt% or more of secologanic acid;
preferably, the honeysuckle extract contains 80 wt% or more of secologanic acid;
more preferably, the honeysuckle extract contains 90 wt% or more of secologanic acid. - The pharmaceutical kit according to claim 6, wherein the honeysuckle extract is prepared by a method comprising the following steps:(1) pulverizing honeysuckle of plants, its original plant of lonicera japonica or other congeneric plants, and then performing extraction with C1-C6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain an extract;(2) concentrating the extract obtained in step (1) under normal or reduced pressure to obtain an extractum, or performing spray-drying on the extract obtained in step (1) to obtain powder, and dissolving the extractum or powder with water, then carrying out precipitation or settlement with C1-C6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain a precipitate or a dissolving liquid concentrate;(3) isolating and purifying the precipitate or dissolving liquid concentrate obtained in step (2) by chromatography, and collecting eluate containing iridoid compounds, wherein the chromatography is selected from one or more of macroporous adsorption resin column chromatography, normal phase silica gel chromatography and reversed phase silica gel chromatography;preferably, the honeysuckle extract is prepared by a method comprising the following steps:(1) pulverizing honeysuckle herbs and then performing extraction with 50% (v/v) ethanol aqueous solution to obtain an extracted liquid;(2) concentrating the extracted liquid obtained in step (1) under reduced pressure to obtain an extractum, dissolving the extractum with water, filtering, and concentrating the solution to dryness, and performing dissolution by adding 95% (v/v) ethanol aqueous solution, and adding distilled water to make the solution contain 75% (v/v) ethanol, filtering after standing, and recovering ethanol from the filtrate to obtain a fluid extractum;(3) dissolving the fluid extractum obtained in step (2) by adding water and filtering to obtain a filtrate, and making the filtrate pass through a styrene macroporous adsorption resin chromatographic column, and then eluting the column sequentially with water and 20% (v/v) ethanol aqueous solution, and recovering ethanol in the eluate of 20% (v/v) ethanol aqueous solution;more preferably, the method further comprises the step of purifying the eluate containing iridoid compounds obtained in step (3) by gel chromatography;
most preferably, the method further comprises the step of purifying the eluate containing iridoid compounds obtained in step (3) by Sephadex LH-20 gel chromatographic column and collecting the eluate of water. - The pharmaceutical composition according to claim 1 or the pharmaceutical kit according to claim 6 for use in the prevention and/or treatment of a disease caused by a bacterium, wherein the bacterium is preferably an antibiotic-resistant bacterium, and more preferably a multiple antibiotic-resistant bacterium.
- The pharmaceutical composition or the pharmaceutical kit according to the use of claim 10, wherein the bacterium is selected from a multiple antibiotic-resistant gram-negative bacterium;
preferably, the multiple antibiotic-resistant gram-negative bacterium is selected from one or more of the group consisting of Escherichia coli, Pseudomona aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Proteus bacillus, enterobacteriaceae, Haemophilus influenzae, pneumobacillus and catarrhalis;
more preferably, the multiple antibiotic-resistant gram-negative bacterium is Escherichia coli, Pseudomona aeruginosa and/or Klebsiella pneumoniae; or
a multiple antibiotic-resistant gram-positive bacterium;
preferably, the multiple antibiotic-resistant gram-positive bacterium is selected from one or more of the group consisting of Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Group A Streptococcus pyogenes, Streptococcus pneumoniae, Bacillus subtilis and Staphylococcus epidermidis;
further preferably, the multiple antibiotic-resistant gram-positive bacterium is methicillin-resistant Staphylococcus aureus and/or Staphylococcus aureus. - The pharmaceutical composition or the pharmaceutical kit according to the use of claim 10, wherein the disease caused by a bacterium is an infectious disease caused by a bacterium, especially one or more of infectious diseases caused by antibiotic-resistant bacteria, such as digestive system infection; blood system infection; respiratory system infection; urinary tract infection; central nervous system infection; bone and joint infection; ear, mastoid and/or sinus infection; and skin and soft tissue infection;
preferably, the disease caused by a bacterium is respiratory system infection caused by the antibiotic-resistant bacterium. - The pharmaceutical composition or the pharmaceutical kit according to the use of claim 12, wherein the disease caused by a bacterium is respiratory system infection caused by a multiple antibiotic-resistant gram-negative bacterium;
further preferably, the disease caused by a bacterium is infectious pneumonia caused by a multiple antibiotic-resistant gram-negative bacterium;
more preferably, the disease caused by a bacterium is nosocomial infectious pneumonia caused by a multiple antibiotic-resistant gram-negative bacterium; more preferably, the disease caused by a bacterium is nosocomial infectious pneumonia caused by a multiple antibiotic-resistant Klebsiella pneumoniae. - The pharmaceutical composition or the pharmaceutical kit according to the use of claim 12, wherein the disease caused by a bacterium is respiratory system infection caused by a multiple antibiotic-resistant gram-positive bacterium;
preferably, the disease caused by a bacterium is pneumonia caused by a multiple antibiotic-resistant gram-positive bacteria;
further preferably, the disease caused by a bacterium is pneumonia caused by methicillin-resistant Staphylococcus aureus. - Honeysuckle extract containing iridoid compounds for use in the reverting of resistance of bacteria, wherein the honeysuckle extract contains secologanic acid represented by the following structural formula (1):
- The honeysuckle extract according to the use of claim 15, wherein the honeysuckle extract contains 70 wt% or more of secologanic acid;
preferably, the honeysuckle extract contains 80 wt% or more of secologanic acid;
more preferably, the honeysuckle extract contains 90 wt% or more of secologanic acid. - The honeysuckle extract according to the use of claim 15, wherein the honeysuckle extract is prepared by a method comprising the following steps:(1) pulverizing honeysuckle of plants, its original plant of lonicera japonica or other congeneric plants, and then performing extraction with C1-C6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain an extract;(2) concentrating the extract obtained in step (1) under normal or reduced pressure to obtain an extractum, or performing spray-drying on the extract obtained in step (1) to obtain powder, and dissolving the extractum or powder with water, then carrying out precipitation or settlement with C1-C6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain a precipitate or a dissolving liquid concentrate;(3) isolating and purifying the precipitate or dissolving liquid concentrate obtained in step (2) by chromatography, and collecting eluate containing iridoid compounds, wherein the chromatography is selected from one or more of macroporous adsorption resin column chromatography, normal phase silica gel chromatography and reversed phase silica gel chromatography;preferably, the honeysuckle extract is prepared by a method comprising the following steps:(1) pulverizing honeysuckle herbs and then performing extraction with 50% (v/v) ethanol aqueous solution to obtain an extracted liquid;(2) concentrating the extracted liquid obtained in step (1) under reduced pressure to obtain an extractum, dissolving the extractum with water, filtering, and concentrating the solution to dryness, and performing dissolution by adding 95% (v/v) ethanol aqueous solution, and adding distilled water to make the solution contain 75% (v/v) ethanol, filtering after standing, and recovering ethanol from the filtrate to obtain a fluid extractum;(3) dissolving the fluid extractum obtained in step (2) by adding water and filtering to obtain a filtrate, and making the filtrate pass through a styrene macroporous adsorption resin chromatographic column, and then eluting the column sequentially with water and 20% (v/v) ethanol aqueous solution, and recovering ethanol in the eluate of 20% (v/v) ethanol aqueous solution;more preferably, the method further comprises the step of purifying the eluate containing iridoid compounds obtained in step (3) by gel chromatography;
most preferably, the method further comprises the step of purifying the eluate containing iridoid compounds obtained in step (3) by Sephadex LH-20 gel chromatographic column and collecting the eluate of water. - The honeysuckle extract according to the use of claim 15, wherein the resistance of bacteria is resistance of bacteria to antibiotics;
preferably, the resistance of bacteria is resistance of bacteria to multiple antibiotics;
further preferably, the antibiotic is selected from one or more of the group consisting of ampicillin, penam sulfone, piperacillin, tazobactam, amoxicillin, clavulanic acid, cefazolin, cefuroxime, ceftriaxone, cefuroxime sodium, sulperazon, levofloxacin, cefotaxime, ceftazidime, imipenem, cefepime, cefoxitin, gentamicin, amikacin, ciprofloxacin, chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, nitrofurantoin, aztreonam, norfloxacin, sulbactam, ticarcillin, tobramycin, tazocin, minocycline, meropenem, penicillin, oxacillin, erythromycin, vancomycin, rifampin and clindamycin;
preferably, the antibiotic is ampicillin and/or erythromycin. - The honeysuckle extract according to the use of claim 15, wherein the drug further contains an antibiotic;
preferably, the drug is selected from one or more of the group consisting of ampicillin, penam sulfone, piperacillin, tazobactam, amoxicillin, clavulanic acid, cefazolin, cefuroxime, ceftriaxone, cefuroxime sodium, sulperazon, levofloxacin, cefotaxime, ceftazidime, imipenem, cefepime, cefoxitin, gentamicin, amikacin, ciprofloxacin, chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, nitrofurantoin, aztreonam, norfloxacin, sulbactam, ticarcillin, tobramycin, tazocin, minocycline, meropenem, penicillin, oxacillin, erythromycin, vancomycin, rifampin and clindamycin;
more preferably, the antibiotic is ampicillin and/or erythromycin.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2011/078331 WO2013023338A1 (en) | 2011-08-12 | 2011-08-12 | Pharmaceutical composition containing honeysuckle extract and antibiotics, pharmaceutical kit, and use of honeysuckle extract for preparation of drug |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2743275A1 EP2743275A1 (en) | 2014-06-18 |
EP2743275A4 EP2743275A4 (en) | 2015-04-08 |
EP2743275B1 true EP2743275B1 (en) | 2018-10-10 |
Family
ID=47714676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11870857.7A Active EP2743275B1 (en) | 2011-08-12 | 2011-08-12 | Pharmaceutical composition containing honeysuckle extract and antibiotics, pharmaceutical kit, and medical use of honeysuckle extract |
Country Status (6)
Country | Link |
---|---|
US (1) | US9849145B2 (en) |
EP (1) | EP2743275B1 (en) |
JP (1) | JP5980925B2 (en) |
CN (1) | CN103732609B (en) |
RU (1) | RU2571281C2 (en) |
WO (1) | WO2013023338A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104306594A (en) * | 2014-11-03 | 2015-01-28 | 李正梅 | Traditional Chinese medicine for curing common cold of wind-heat, and preparation method and application method thereof |
CN105585600B (en) * | 2015-11-30 | 2019-03-08 | 江苏康缘药业股份有限公司 | A kind of preparation method of disconnected oxidation loganin |
CN106511728B (en) * | 2017-01-13 | 2021-09-17 | 承德医学院 | Preparation method of gardenia golden flower dropping pills |
US10251832B2 (en) | 2017-05-26 | 2019-04-09 | Mary Kay Inc. | Cosmetic compositions and methods |
CN110438198B (en) * | 2019-09-05 | 2023-07-21 | 湖南农业大学 | Ramie variety and organ screening method for preparing antibiotics based on grass meal extract |
KR102489659B1 (en) * | 2020-07-20 | 2023-01-18 | 경북대학교 산학협력단 | Composition of antimicrobial complex for animal comprising amphenicols and aminoglycosides |
RU2755817C1 (en) * | 2020-07-22 | 2021-09-21 | Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" | Method for reducing gram-positive avian gut microbiota |
CN111904995B (en) * | 2020-08-04 | 2022-03-01 | 南方医科大学 | Application of prunella vulgaris combined antibiotic in preparation of medicine for resisting multidrug-resistant staphylococcus aureus |
CN115160251B (en) * | 2022-08-11 | 2023-10-24 | 山东省分析测试中心 | N-N-bis-oxazolidinone alkaloid compound, preparation method and application thereof in medicine field |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
KR100396184B1 (en) * | 2002-07-29 | 2003-08-27 | (주) 바이오스킨테크 | Natural antibiotic composition |
US7314644B2 (en) * | 2002-09-11 | 2008-01-01 | Sk Chemicals Co., Ltd. | Extraction and purification method of active constituents from stem of Lonicera japonica thunb., its usage for anti-inflammatory and analgesic drug |
CN100575358C (en) * | 2006-06-07 | 2009-12-30 | 石家庄汉康生化药品有限公司 | Flos Lonicerae extract, its preparation method and application |
CN1969960A (en) | 2006-12-01 | 2007-05-30 | 朱天娇 | Pharmaceutical composition for treating acne and application method thereof |
DE102009012455A1 (en) * | 2009-03-12 | 2010-09-23 | Follmann & Co. Gesellschaft Für Chemie-Werkstoffe Und -Verfahrenstechnik Mbh & Co. Kg | Improved microcapsules and their preparation |
-
2011
- 2011-08-12 CN CN201180072836.7A patent/CN103732609B/en active Active
- 2011-08-12 RU RU2014104754/15A patent/RU2571281C2/en active
- 2011-08-12 US US14/238,448 patent/US9849145B2/en active Active
- 2011-08-12 WO PCT/CN2011/078331 patent/WO2013023338A1/en active Application Filing
- 2011-08-12 EP EP11870857.7A patent/EP2743275B1/en active Active
- 2011-08-12 JP JP2014525273A patent/JP5980925B2/en active Active
Non-Patent Citations (2)
Title |
---|
GIOVANNI BONFIGLIO: "Is Levofloxacin as Active as Ciprofloxacin against <i>Pseudomonas aeruginosa</i>?", CHEMOTHERAPY, vol. 47, no. 4, 23 May 2001 (2001-05-23), CH, pages 239 - 242, XP055308340, ISSN: 0009-3157, DOI: 10.1159/000048529 * |
LORENZO DRAGO ET AL: "Activity of Levofloxacin and Ciprofloxacin in Combination with Cefepime, Ceftazidime, Imipenem, Piperacillin-Tazobactam and Amikacin against Different <i>Pseudomonas aeruginosa</i> Phenotypes and <i>Acinetobacter</i> spp.", CHEMOTHERAPY, vol. 50, no. 4, 1 January 2004 (2004-01-01), CH, pages 202 - 210, XP055308336, ISSN: 0009-3157, DOI: 10.1159/000081033 * |
Also Published As
Publication number | Publication date |
---|---|
CN103732609B (en) | 2016-08-24 |
EP2743275A4 (en) | 2015-04-08 |
EP2743275A1 (en) | 2014-06-18 |
RU2571281C2 (en) | 2015-12-20 |
US9849145B2 (en) | 2017-12-26 |
JP5980925B2 (en) | 2016-08-31 |
WO2013023338A1 (en) | 2013-02-21 |
US20140193530A1 (en) | 2014-07-10 |
JP2014525923A (en) | 2014-10-02 |
RU2014104754A (en) | 2015-09-20 |
CN103732609A (en) | 2014-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2743275B1 (en) | Pharmaceutical composition containing honeysuckle extract and antibiotics, pharmaceutical kit, and medical use of honeysuckle extract | |
Liu et al. | Baicalin synergy with β‐lactam antibiotics against methicillin‐resistant Staphylococcus aureus and other β‐lactam‐resistant strains of S. aureus | |
Biradar et al. | Exploring of antimicrobial activity of Triphala Mashi—An ayurvedic formulation | |
Parameswari et al. | In vitro anti-inflammatory and antimicrobial potential of leaf extract from Artemisia nilagirica (Clarke) Pamp | |
Dubey et al. | Antibacterial activity of Lantana camara L. against multidrug resistant pathogens from ICU patients of a teaching hospital | |
Uddin et al. | Antibacterial activity of the ethanol extracts of Hibiscus rosa-sinensis leaves and flowers against clinical isolates of bacteria | |
WO2009050451A1 (en) | Antibacterial composition comprising salvia extracts | |
Senhaji et al. | Mineral composition, in vitro inhibitory effects of α-amylase, α-glucosidase, β-galactosidase enzymes and antibacterial activity of Ajuga Iva subsp. Pseudoiva (DC.) Bric | |
KR101142598B1 (en) | An Antibacterial composition comprising the essential oil extract of Kjellemaiella crassifolia and the compounds isolated therefrom | |
CN103889430B (en) | A kind of Flos Lonicerae extract, comprise its medical composition and its use | |
CN104000881A (en) | Effective humulus scandens part with antibacterial activity and application thereof | |
US20100323046A1 (en) | Novel uses of hibiscus, in particular pharmaceutical uses | |
CN100471851C (en) | Lignin in dandelion, its bacteria-resisting activity and use for medicine | |
CN102670674A (en) | Geranium strictipes R. Knuth effective part extract as well as preparation method and drug application | |
CN103040897B (en) | Application of Qingkailing active component radix isatidis extract in preparation of anti-multidrug-resistant bacterium medicine | |
CN103889431B (en) | Secologanic acid, comprise its medical composition and its use | |
Gheisari et al. | Antibacterial effects of hydro-alcoholic extract of pennyroyal, cinnamon and rhubarb on Klebsiella pneumoniae and Staphylococcus aureus: An in-vitro study | |
Aliasghari et al. | Antibacterial Effects of Camellia sinensis and Achillea millefolium on several antibiotic-resistant bacteria | |
Triveni et al. | Phytochemical Analysis, Antibiofilm And Antibacterial Activity Of Crude Methanol Extract Of Careya arborea Roxb. Fruit Against Multi Drug Resistant Strains | |
Sangeetha et al. | Antibacterial Efficiency and Phytochemical Assessment of Stereospermum Chelonoides (LF) DC Flower and Leaf Mixed Powder Extracts.(2022) | |
Ngente et al. | Antimicrobial activity of methanol extract of root bark of Hiptage benghalensis (L) Kurz | |
Masoko et al. | Stomatostemma monteiroae: A food plant with potential medicinal and therapeutic values | |
Alghamdi et al. | Antibacterial power of Pomegranate extracts against Beta-Lactamase producing Escherichia coli | |
Osman et al. | Phytochemical screening and antibacterial activity of Portulaca oleracea L. extracts against antibiotic-resistant bacteria | |
Kirubanandan et al. | Evaluation of antimicrobial potential of aqueous and alcoholic extract of Triphala against wound pathogens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140212 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07H 17/04 20060101AFI20150226BHEP Ipc: A61P 31/04 20060101ALI20150226BHEP Ipc: A61K 31/7042 20060101ALI20150226BHEP Ipc: A61K 36/355 20060101ALI20150226BHEP |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150309 |
|
17Q | First examination report despatched |
Effective date: 20161018 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180102 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTC | Intention to grant announced (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180621 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SHI, JIANGONG Inventor name: LI, ZHULAN Inventor name: ZHANG, TIEJUN Inventor name: MA, XUWEI Inventor name: HAN, FENGNIAN Inventor name: MENG, HONG |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1051093 Country of ref document: AT Kind code of ref document: T Effective date: 20181015 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011052882 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20181010 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1051093 Country of ref document: AT Kind code of ref document: T Effective date: 20181010 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190110 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190210 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190110 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190210 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190111 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011052882 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 |
|
26N | No opposition filed |
Effective date: 20190711 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190812 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20190831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20110812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181010 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230824 Year of fee payment: 13 Ref country code: DE Payment date: 20230821 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240603 Year of fee payment: 14 |